{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T20:25:00Z","timestamp":1787430300144,"version":"build-2736575974"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s12325-026-03648-7","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T04:01:02Z","timestamp":1780718462000},"page":"3675-3684","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Obesity, Liver Disease, and the Patient Voice: A Clinical Dialogue Podcast"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3329-5621","authenticated-orcid":false,"given":"Megha","family":"Poddar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Nadglowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,6]]},"reference":[{"issue":"9","key":"3648_CR1","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1038\/s41591-024-03095-3","volume":"30","author":"L Busetto","year":"2024","unstructured":"Busetto L, Dicker D, Fruhbeck G, et al. A new framework for the diagnosis, staging and management of obesity in adults. Nat Med. 2024;30(9):2395\u20139. https:\/\/doi.org\/10.1038\/s41591-024-03095-3.","journal-title":"Nat Med"},{"issue":"3","key":"3648_CR2","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S2213-8587(24)00316-4","volume":"13","author":"F Rubino","year":"2025","unstructured":"Rubino F, Cummings DE, Eckel RH, et al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol. 2025;13(3):221\u201362. https:\/\/doi.org\/10.1016\/S2213-8587(24)00316-4.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10481","key":"3648_CR3","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0140-6736(25)00355-1","volume":"405","author":"GBD 2021 Adult BMI Collaborators","year":"2025","unstructured":"GBD 2021 Adult BMI Collaborators. Global, regional, and national prevalence of adult overweight and obesity, 1990\u20132021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021. Lancet. 2025;405(10481):813\u201338. https:\/\/doi.org\/10.1016\/S0140-6736(25)00355-1.","journal-title":"Lancet"},{"key":"3648_CR4","unstructured":"World Obesity Federation. World obesity atlas 2025. London: World Obesity Federation; 2025. https:\/\/data.worldobesity.org\/publications\/?cat=23. Accessed 9 Apr 2026."},{"issue":"8","key":"3648_CR5","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1111\/dom.13752","volume":"21","author":"ID Caterson","year":"2019","unstructured":"Caterson ID, Alfadda AA, Auerbach P, et al. Gaps to bridge: misalignment between perception, reality and actions in obesity. Diabetes Obes Metab. 2019;21(8):1914\u201324. https:\/\/doi.org\/10.1111\/dom.13752.","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"3648_CR6","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13120","volume":"21","author":"E Atlantis","year":"2020","unstructured":"Atlantis E, Sahebolamri M, Cheema BS, Williams K. Usefulness of the Edmonton Obesity Staging System for stratifying the presence and severity of weight-related health problems in clinical and community settings: a rapid review of observational studies. Obes Rev. 2020;21(11):e13120. https:\/\/doi.org\/10.1111\/obr.13120.","journal-title":"Obes Rev"},{"issue":"1","key":"3648_CR7","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/S2468-1253(22)00317-X","volume":"8","author":"J Quek","year":"2023","unstructured":"Quek J, Chan KE, Wong ZY, et al. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023;8(1):20\u201330. https:\/\/doi.org\/10.1016\/S2468-1253(22)00317-X.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"3648_CR8","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.cld.2023.01.002","volume":"27","author":"F Bril","year":"2023","unstructured":"Bril F, Sanyal A, Cusi K. Metabolic syndrome and its association with nonalcoholic steatohepatitis. Clin Liver Dis. 2023;27(2):187\u2013210. https:\/\/doi.org\/10.1016\/j.cld.2023.01.002.","journal-title":"Clin Liver Dis"},{"issue":"3","key":"3648_CR9","doi-asserted-by":"publisher","DOI":"10.1530\/JOE-24-0115","volume":"262","author":"G Sancar","year":"2024","unstructured":"Sancar G, Birkenfeld AL. The role of adipose tissue dysfunction in hepatic insulin resistance and T2D. J Endocrinol 2024;262(3):e240115. https:\/\/doi.org\/10.1530\/JOE-24-0115.","journal-title":"J Endocrinol"},{"key":"3648_CR10","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.coph.2020.10.016","volume":"55","author":"S Guerra","year":"2020","unstructured":"Guerra S, Gastaldelli A. The role of the liver in the modulation of glucose and insulin in non alcoholic fatty liver disease and type\u00a02 diabetes. Curr Opin Pharmacol. 2020;55:165\u201374. https:\/\/doi.org\/10.1016\/j.coph.2020.10.016.","journal-title":"Curr Opin Pharmacol"},{"key":"3648_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ejim.2023.11.005","volume":"122","author":"V Lekakis","year":"2024","unstructured":"Lekakis V, Papatheodoridis GV. Natural history of metabolic dysfunction-associated steatotic liver disease. Eur J Intern Med. 2024;122:3\u201310. https:\/\/doi.org\/10.1016\/j.ejim.2023.11.005.","journal-title":"Eur J Intern Med"},{"issue":"3","key":"3648_CR12","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3350\/cmh.2023.0384","volume":"30","author":"J Hwang","year":"2024","unstructured":"Hwang J, Hwang H, Shin H, et al. Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: a systematic review and meta-analysis. Clin Mol Hepatol. 2024;30(3):561\u201376. https:\/\/doi.org\/10.3350\/cmh.2023.0384.","journal-title":"Clin Mol Hepatol"},{"issue":"4","key":"3648_CR13","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","volume":"391","author":"R Loomba","year":"2024","unstructured":"Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med. 2024;391(4):299\u2013310. https:\/\/doi.org\/10.1056\/NEJMoa2401943.","journal-title":"N Engl J Med"},{"issue":"21","key":"3648_CR14","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","volume":"392","author":"AJ Sanyal","year":"2025","unstructured":"Sanyal AJ, Newsome PN, Kliers I, et al. Phase\u00a03 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025;392(21):2089\u201399. https:\/\/doi.org\/10.1056\/NEJMoa2413258.","journal-title":"N Engl J Med"},{"issue":"5","key":"3648_CR15","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1053\/j.gastro.2025.02.044","volume":"169","author":"ZM Younossi","year":"2025","unstructured":"Younossi ZM, Zelber-Sagi S, Lazarus JV, et al. Global consensus recommendations for metabolic dysfunction-associated steatotic liver disease and steatohepatitis. Gastroenterology. 2025;169(5):1017-1032 e2. https:\/\/doi.org\/10.1053\/j.gastro.2025.02.044.","journal-title":"Gastroenterology"},{"issue":"3","key":"3648_CR16","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","volume":"81","author":"European Association for the Study of the Liver (EASL)","year":"2024","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). J Hepatol. 2024;81(3):492\u2013542. https:\/\/doi.org\/10.1016\/j.jhep.2024.04.031.","journal-title":"J Hepatol"},{"issue":"1 Suppl 1","key":"3648_CR17","doi-asserted-by":"publisher","first-page":"S59","DOI":"10.2337\/dc25-S004","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","unstructured":"American Diabetes Association Professional Practice Committee. 4. Comprehensive medical evaluation and assessment of comorbidities: standards of care in diabetes-2025. Diabetes Care. 2025;48(1 Suppl 1):S59\u201385. https:\/\/doi.org\/10.2337\/dc25-S004.","journal-title":"Diabetes Care"},{"issue":"5","key":"3648_CR18","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797\u2013835. https:\/\/doi.org\/10.1097\/HEP.0000000000000323.","journal-title":"Hepatology"},{"issue":"1S Suppl 1","key":"3648_CR19","doi-asserted-by":"publisher","first-page":"e986","DOI":"10.1097\/MEG.0000000000002340","volume":"33","author":"D Ouzan","year":"2021","unstructured":"Ouzan D, Mosnier A, Penaranda G, et al. Prospective screening for significant liver fibrosis by fibrosis-4 in primary care patients without known liver disease. Eur J Gastroenterol Hepatol. 2021;33(1S Suppl 1):e986\u201391. https:\/\/doi.org\/10.1097\/MEG.0000000000002340.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"3648_CR20","unstructured":"Kalra A, Yetiskul E, Wehrle CJ, Tuma F. Physiology, liver. Treasure Island: StatPearls; 2026."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03648-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03648-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03648-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T20:01:35Z","timestamp":1787428895000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03648-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,6]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["3648"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03648-7","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,6]]},"assertion":[{"value":"22 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Megha Poddar reports receiving royalties or licences from the Medical Weight Management Centre of Canada; consulting fees and honoraria for education in obesity and diabetes management from Bausch Health, Novo Nordisk, Eli Lilly, EOCI Pharmacomm, CCRN, Janssen, Merck, Antibody Solutions, CPD Network Association, Johnson & Johnson, Boehringer Ingelheim, Rhythm Pharmaceuticals, and the College of Physicians and Surgeons of Ontario; and travel support from Bausch Health, Novo Nordisk, and Eli Lilly. Dr. Poddar has participated on the data safety monitoring board for the OK-TRANSPLANT-2 clinical trial and serves as a chief medical officer for Nymble Health and medical adviser for Shoppers Drug Mart. Joe Nadglowski is an employee of the Obesity Action Coalition.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}